title: Drug development. Orphan drug windfalls?
authors.forename: D
authors.initials: D
authors.lastname: Gershon
mesh_terms: D001709:Biotechnology / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D005776:Gaucher Disease / Q000188:drug therapy / Q000191:economics; D005962:Glucosylceramidase / Q000627:therapeutic use; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007880:Legislation, Drug; D009965:Orphan Drug Production / Q000191:economics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011994:Recombinant Proteins; C070292:alglucerase; D013006:Growth Hormone; D005962:Glucosylceramidase